Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes

Drug Metabolism and Disposition

Volumn 24, Issue 9, 1996, Pages 1002-1008

  Torchin, Cynthia D ^a   McNeilly, Patrick J ^b   Kapetanovic, Izet M ^a,c   Strong, John M ^b   Kupferberg, Harvey J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADD 137022; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ENZYME INHIBITOR; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LOSIGAMONE; PHENYTOIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ELECTROCHEMICAL DETECTION; ENANTIOMER; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MASS SPECTROMETRY; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOCHEMISTRY; ULTRAVIOLET SPECTROSCOPY;

ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COUMARINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FURANS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PHENYTOIN; RECOMBINANT PROTEINS; STEREOISOMERISM; TRIAZINES;

EID: 0029813840     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. R. J. Porter: Classification of epileptic seizures and epileptic syndromes. In "A Textbook of Epilepsy" (J. Laidlaw and D. Chadwick, eds.), pp. 1-22. Churchill Livingstone, New York, 1993.
2. M. Noldner, S. S. Chatterjee, U. Stein, and U. Heinemann: Losigamone. Drugs Future 15, 995-996 (1990).
3. C. L. Zhang, S. S. Chatterjee, U. Stein, and U. Heinemann: Comparison of the effects of losigamone and its isomers on maximal electroshock induced convulsions in mice and on three different patterns of low magnesium induced epileptiform activity in slices of the rat temporal cortex. Naunyn-Schmiedebergs Arch. Pharmacol. 345, 85-92 (1992).
4. U. Stein: Potential antiepileptic drugs: losigamone. In "Antiepileptic Drugs" (R. H. Levy, R. H. Mattson, and B. S. Meldrum, eds.), pp. 1025-1034. Raven Press, New York, 1995.
5. C. A. Jamis-Dow, R. W. Klecker, A. G. Katki, and J. M. Collins: Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother. Pharmacol. 36, 107-114 (1995).
6. S. M. Lunte, D. M. Radzik, and P. T. Kissinger: An introduction to the study of xenobiotic metabolism using electroanalytical techniques. J. Pharm. Sci. 79, 557-567 (1990).
7. K. R. Korzekwa, D. C. Swinney, and W. F. Trager: Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation. Biochemistry 28, 9019-9027 (1989).
8. K. Lertratanangkoon and M. G. Horning: Metabolism of carbamazepine. Drug Metab. Dispos. 10, 1-10 (1982).
9. J. H. Maguire and J. S. McClanahan: Evidence for stereoselective production of phenytoin (5,5-diphenylhydantoin) arene oxides in man. Adv. Exp. Med. Biol. 197, 897-902 (1986).
10. M. G. Horning: Metabolism of N,2-dimethyl-2-phenylsuccinimide (methsuximide) by epoxide-diol pathway in rat, guinea pig, and human. Res. Commun. Chem. Pathol. Pharmacol. 6, 565-578 (1973).
11. A. D. Rodrigues: Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochem. Pharmacol. 48, 2147-2156 (1994).
12. M. Eichelbaum: Enantiomers: implications and complications in developmental pharmacology. Dev. Pharmacol. Ther. 18, 131-134 (1992).
13. M. Eichelbaum: Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem. Pharmacol. 37, 93-96 (1988).
14. K. Williams and E. Lee: Importance of drug enantiomers in clinical pharmacology. Drugs 30, 333-354 (1985).
15. E. J. D. Lee and K. M. Williams: Chirality: clinical pharmacokinetic and pharmacodynamic considerations. Clin. Pharmacokinet. 18, 339-345 (1990).
16. H. K. Kroemer, C. Fischer, C. O. Meese, and M. Eichelbaum: Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. Mol. Pharmacol. 40, 135-142 (1991).
17. H. K. Kroemer, M. F. Fromm, K. Buhl, H. Terefe, G. Blaschke, and M. Eichelbaum: An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation 89, 2396-2400 (1994).
18. T. Ebner, C. O. Meese, and M. Eichelbaum: Regioselectivity and stereoselectivity of the metabolism of the chiral quinolizidine alkaloids sparteine and pachycarpine in the rat. Xenobiotica 21, 847-857 (1991).
19. S. Fujita, S. Umeda, Y. Funae, S. Imaoka, H. Abe, R. Ishida, T. Adachi, M. Masuda, A. Kazusaka, and T. Suzuki: Regie- and stereoselective propranolol metabolism by 15 forms of purified cytochromes P-450 from rat liver. J. Pharmacol. Exp. Ther. 264, 226-233 (1993).
20. B. E. Daikh, J. M. Lasker, J. L Raucy, and D. R. Koop: Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 271, 1427-1433 (1994).
21. D. S. Mautz, W. L. Nelson, and D. D. Shen: Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab. Dispos. 23, 513-517 (1995).
22. A receptor system. Epilepsia 36, 983-989 (1995).
23. H. K. Kroemer, H. Echizen, H. Heidemann, and M. Eichelbaum: Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther. 260, 1052-1057 (1992).